NCT00055718View on ClinicalTrials.gov

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2001

Study Completion Date

January 31, 2010

Conditions

Drug/Agent Toxicity by Tissue/OrganLeukemia

Interventions

DIETARY_SUPPLEMENT

silymarin

Trial Locations (8)

10029

Mount Sinai School of Medicine, New York

10032

Herbert Irving Comprehensive Cancer Center at Columbia University, New York

11501

Winthrop University Hospital, Mineola

19104

Children's Hospital of Philadelphia, Philadelphia

33155

Miami Children's Hospital, Miami

44308-1062

Children's Hospital Medical Center of Akron, Akron

98105-3916

Children's Hospital and Regional Medical Center - Seattle, Seattle

L8N 3Z5

McMaster Children's Hospital at Hamilton Health Sciences, Hamilton

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Herbert Irving Comprehensive Cancer Center

OTHER

NCT00055718 - Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy | Biotech Hunter | Biotech Hunter